# Notch Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/notch-therapeutics

- Industry: Biotechnology
- Headquarters: Toronto, Canada
- Website: www.notchtx.com
- Total disclosed funding: $85M
- Latest round: Series A (Feb 10, 2021)
- Investors on record: 7

## About

Founded in 2018 and based in Toronto, Canada, Notch Therapeutics, Inc. operates as a biotechnology company that develops immunotherapy drugs. The company was founded by Sunnybrook Research Institute and the University of Toronto. In February 2021, Notch Therapeutics, Inc. received USD 85 million in series A funding from Allogene Therapeutics, Inc., Lumira Ventures, CCRM Enterprises Holdings Ltd., EcoR1 Capital, Casdin Capital, Samsara BioCapital, and Amplitude Ventures.

The company develops a pipeline of cellular immunotherapies intended to generate T cells and other immune cells from the clonal stem. The company produces stem cell-derived, gene-edited immune cell therapies and the differentiation of induced pluripotent stem cells without the use of any animal components.

The company's revenue is generated from developing immunotherapy drugs in the field of cancer.

Notch Therapeutics, Inc. plans to continue the development of Notch's portfolio. The company also plans to expand its team.

## Funding rounds

- Series A, Feb 10, 2021, $85M — Casdin Capital, EcoR1 Capital, Samsara BioCapital, Allogene Therapeutics, Inc., Amplitude, Centre for Commercialization of Regenerative Medicine, Lumira Ventures

## Investors

- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series A
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A
- Allogene Therapeutics, Inc. — Series A
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Series A
- Centre for Commercialization of Regenerative Medicine — Series A
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A